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Concurrent JAK2 V617F Acute Myeloid Leukemia
(AML) and Leukemic non-nodal Mantle Cell Lymphoma
(LN-MCL): Case study
H. Ohan, K. Inamdar, Y. Shen, W. liu, J.C. Gomez-Gelvez,
S. Ghosh; Pathology, Henry Ford Hospital, Detroit,
Michigan, UNITED STATES
Introduction/Objective: We report a unique case of concurrently occurring Acute Myeloid Leukemia (AML) and
Leukemic non-nodal Mantle Cell Lymphoma (LN-MCL)
in an 86-year-old male. To the best of our knowledge, this
is the first report of AML occurring in the background of
LN-MCL, with no known history of any malignancy or
chemotherapy.
Methods/Case Report: An 86-year old Caucasian male
with unremarkable past medical history presented
with pancytopenia, fatigue and generalized weakness.
Abdominal CT scan was negative for lymphadenopathy or hepatosplenomegaly. Peripheral blood showed
2% blasts with atypical lymphocytes 89%. Bone marrow
aspirate showed 30% myeloblasts expressing CD34,
CD117, CD13, CD33, HLA-DR and CD56 (dim) by
flow cytometry (FC). Lymphocytes accounted for 40%
of bone marrow cellularity. FC identified a population of
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CD5+ kappa restricted clonal B cells 2%, consistent with
a concurrent CD5+ B-lymphoproliferative disorder/lymphoma. The bone marrow biopsy was inadequate for further evaluation of the B- cell lymphoma. Chromosomal
analysis revealed a normal male karyotype. FISH analysis was positive for t(11:14) CCND1::IGH rearrangement (in 3.5% of interphase cells) supporting involvement
by MCL. Myeloid panel next generation sequencing (51
genes) was positive for JAK2 V617F (VAF, 38%) and
ASXL1 P920Tfs*4 (VAF, 22%) variants
Results (if a Case Study enter NA): NA
Conclusion: Concurrent presence of LN-MCL and
AML as seen in our patient in the absence of prior history of malignancy or chemotherapy is rare. Presence of
JAK2V617F mutation in de-novo AML is extremely rare
(<5%). There is no prior history of myeloproliferative neoplasm (MPN) or CBC data to suggest that this may have
progressed from an MPN. While the absence of lymphadenopathy suggests that the CD5+ B-LPD likely represents
LN-MCL, it is also likely that the CD5+, IgH/CCND1
rearranged B-cells may represent prior undetected circulating cells without overt LN-MCL development, similar
to those reported in otherwise healthy individuals. It is unclear but tempting to speculate that the two co-occurring
hematologic malignancies may have a common cell of
origin
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Introduction/Objective: BTEX (benzene, toluene, ethylbenzene, and xylene) is well know for its toxicity via
through environmental, occupational and recreational
exposures. However, there is limited literature about the
carcinogenic effect of BTEX. Hence, we aim to study the
prevalence and association of cancer amongst individuals
with exposure of BTEX.
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integrated cameras on microscopes is the mean for whole
slide images (WSI) collection. Image processing refers to
AI/DL spoon-feeding with accurate, diverse and highlydissimilar materials for learning. This requires providing
hundreds of thousands examples of (a) WSI context correction for stain and resolution normalization, (b) cellular
dimensions on the WSI patches for detection, (c) cellular
segmentation/boundaries determination for counting (d)
cellular labels for classification. Comparing with the confirmatory testing results including flow cytometry and
immunohistochemistry is essential in both image processing and validation. Currently, image processing resembles 80-90% of the AI/DL cycle/pipeline which may
take years of hectic work. Our proposed developed tool
enables the Hematopathologists to use pens and draw on
the boundaries of each cell in a field/patch. 3-15 seconds
are needed for each cell. The required ground truth/masks
for segmentation and dimensions for detection are generated in real-time with no need for data scientists.
Results (if a Case Study enter NA): NA
Conclusion: Similar to the automated agile developmentoperation loop concept (DevOps), enabling the
Hematopathologists to perform image processing directly
will reduce the production cycles from years to weeks.
No technology can perform qualitatively better than the
human eyes, the proposed pen-based cell detection and
segmentation tool results in 10-50 fold increase in quality
and quantity. Promisingly, there is a trend among the AI/
DL platforms companies to automate the AI/DL coding.

